Biotech Lock Up Expiration Hell Portfolio: Wave II Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Lock Up Expiration Hell Portfolio: Wave II

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: tuck who wrote (63)	9/20/2004 10:14:38 AM
From: tuck	Read Replies (1) of 107

Immunicon makes a deal: >>HUNTINGDON VALLEY, Pa., Sept. 20 /PRNewswire-FirstCall/ -- Immunicon Corporation (Nasdaq: IMMC - News) announced today that it has entered into an agreement with Quest Diagnostics, Incorporated (NYSE: DGX - News) for the purchase of the Immunicon CellTracks® AutoPrep System and the Immunicon CellSpotter® Analyzer to enable Quest Diagnostics to run the CellSearch(TM) Circulating Tumor Cell Kit, a new cancer diagnostic test that identifies and counts circulating tumor cells ("CTCs") in blood samples from patients being treated for metastatic breast cancer. The CellSearch(TM) Circulating Tumor Cell Kit is manufactured and sold by Veridex, LLC, a Johnson & Johnson company (NYSE: JNJ - News) and incorporates Immunicon proprietary reagents and other technology. Veridex has exclusive worldwide rights to commercialize products incorporating Immunicon technology in the cancer field. As a result of the agreement, Quest Diagnostics will be the only national commercial reference laboratory to offer a test using the Veridex CellSearch(TM) Circulating Tumor Cell Kit. The test will be available later this month to physicians nationwide through Quest Diagnostics Nichols Institute, the company's esoteric testing laboratory located in San Juan Capistrano, California. Terms of the Quest Diagnostics agreement were not disclosed. The August 19, 2004 issue of The New England Journal of Medicine published results of a prospective study sponsored by Immunicon showing that the number of circulating tumor cells in 7.5 mL of blood taken from women with metastatic breast cancer can predict progression-free and overall survival. CTCs are cancer cells that detach from solid tumors and enter the blood stream. Knowing the number of CTCs in the patient's blood may pave the way for oncologists to make critical treatment decisions earlier than previously possible.<< snip Cheers, Tuck

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next